International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

Author Mast, T. Christopher Google Scholar
Kierstead, Lisa Google Scholar
Gupta, Swati B. Google Scholar
Nikas, Alexander A. Google Scholar
Kallas, Esper G. Autor UNIFESP Google Scholar
Novitsky, Vladimir Google Scholar
Mbewe, Bernard Google Scholar
Pitisuttithum, Punee Google Scholar
Schechter, Mauro Google Scholar
Vardas, Eftyhia Google Scholar
Wolfe, Nathan D. Google Scholar
Aste-Amezaga, Miguel Google Scholar
Casimiro, Danilo R. Google Scholar
Coplan, Paul Google Scholar
Straus, Walter L. Google Scholar
Shiver, John W. Google Scholar
Institution Merck Res Labs
Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Harvard Univ
Malawi Coll Med
Mahidol Univ
Universidade Federal do Rio de Janeiro (UFRJ)
Univ Witwatersrand
Johns Hopkins Bloomberg Sch Publ Hlth
Abstract Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors Few studies have described the international epidemiology of pre-existing immunity to adenoviruses We enrolled 1904 participants in a cross-sectional serological survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing antibodies (NA) for adenovirus types Ad5, Ad6, Ad26 and Ad36 Clinical trial samples were used to assess NA titers from the US and Europe the proportions of participants that were negative were 14 8%(Ad5), 31 5%(Ad6),41 2%(Ad26) and 53.6% (Ad36) Adenovirus NA titers varied by geographic location and were higher in non-US and non-European settings, especially Thailand in multivariate logistic regression analysis, geographic setting (non-US and non-European settings) was statistically significantly associated with having higher Ad5 titers, participants from Thailand had the highest odds of having high Ad5 titers (adjusted OR = 3 53,95% CI 224,557) Regardless of location. titers of Ad5NA were the highest and Ad36 NA were the lowest Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations (C) 2009 Published by Elsevier Ltd
Keywords Vector
Adenovirus
HIV
Vaccine
Language English
Date 2010-01-22
Published in Vaccine. Oxford: Elsevier B.V., v. 28, n. 4, p. 950-957, 2010.
ISSN 0264-410X (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 950-957
Origin http://dx.doi.org/10.1016/j.vaccine.2009.10.145
Access rights Closed access
Type Article
Web of Science ID WOS:000274943300017
URI http://repositorio.unifesp.br/handle/11600/32179

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account